Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High …

P Urban, R Mehran, R Colleran, DJ Angiolillo… - Circulation, 2019 - Am Heart Assoc
Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

Coronary stents: current status

S Garg, PW Serruys - Journal of the American College of Cardiology, 2010 - jacc.org
Coronary artery stents revolutionized the practice of interventional cardiology after they were
first introduced in the mid-1980s. Since then, there have been significant developments in …

Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings

K Kolandaivelu, R Swaminathan, WJ Gibson… - Circulation, 2011 - Am Heart Assoc
Background—Stent thrombosis is a lethal complication of endovascular intervention.
Concern has been raised about the inherent risk associated with specific stent designs and …

Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from …

S Bangalore, S Kumar, M Fusaro, N Amoroso… - Circulation, 2012 - Am Heart Assoc
Background—Drug-eluting stents (DES) have been in clinical use for nearly a decade;
however, the relative short-and long-term efficacy and safety of DES compared with bare …

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease …

GG Stefanini, B Kalesan, PW Serruys, D Heg… - The Lancet, 2011 - thelancet.com
Background The effectiveness of durable polymer drug-eluting stents comes at the expense
of delayed arterial healing and subsequent late adverse events such as stent thrombosis …

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice …

EP Navarese, K Tandjung, B Claessen, F Andreotti… - Bmj, 2013 - bmj.com
Objectives To investigate the safety and efficacy of durable polymer drug eluting stents
(DES) and biodegradable polymer biolimus eluting stents (biolimus-ES). Design Network …

Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary …

EH Christiansen, LO Jensen, P Thayssen, HH Tilsted… - The Lancet, 2013 - thelancet.com
Background Third-generation biodegradable polymer drug-eluting stents might reduce the
risk of stent thrombosis compared with first-generation permanent polymer drug-eluting …

Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV

LO Jensen, P Thayssen, EH Christiansen… - Journal of the American …, 2016 - jacc.org
Background: Long-term safety and efficacy for everolimus-eluting stents (EES) versus those
of sirolimus-eluting stents (SES) are unknown. Objectives: This study compared 5-year …

Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All …

S Silber, S Windecker, P Vranckx, PW Serruys - The Lancet, 2011 - thelancet.com
Summary Background In the RESOLUTE All Comers trial, the Resolute zotarolimus-eluting
stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related …

The Western Denmark Heart Registry: its influence on cardiovascular patient care

M Schmidt, M Maeng, M Madsen, HT Sørensen… - Journal of the American …, 2018 - jacc.org
Abstract The WDHR (Western Denmark Heart Registry) is a seminational, multicenter-based
registry with longitudinal registration of detailed patient and procedure data since 1999. The …